Search This Blog

Thursday, December 1, 2022

Aurinia: Britain Marketing Authorization of Lupus Therapy

 MHRA Approval follows European Commission marketing authorization of LUPKYNIS to treat adults with active lupus nephritis in 27 European Union Member States

LUPKYNIS is the first oral medicine approved in the U.S. and Europe for the treatment of adults living with active lupus nephritis

https://finance.yahoo.com/news/aurinia-announces-great-britain-marketing-210500772.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.